Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 June 2022 | Story Leonie Bolleurs | Photo Supplied
Walter van Niekerk_
If you are so focused on achieving only certain goals in your life, you might miss the best opportunities, believes Dr Walter van Niekerk, who recently received his PhD in Agricultural Economics.

Being relevant in a constantly changing agricultural environment. This is one of Dr Walter van Niekerk’s biggest motivations in his working life. The place where he believes he will be able to do just that, is the University of the Free State (UFS). “The university was the best plan for my life,” he says. 

Whether it is in research or in learning and teaching, Dr Van Niekerk, Lecturer in the UFS Department of Agricultural Economics, believes that with a positive attitude and the ability to be adaptable to change, one will be able to make the most of any opportunity crossing your path. If you give 110% every day, you will be ready for any possibility. He is lecturing Agricultural Finance and Agri-business Management, focusing on agricultural business plans, to first- and third-year students, respectively. 

Contribute to findings on predation management

At the recent April graduation ceremonies, he was awarded his PhD. The title of his thesis was: An estimation of the downstream economic implications of predation in the South African red meat industry.

In his thesis, he outlined the economic impact of predation in the livestock sector and red meat industry. He believes the significant damage caused by predators cannot be controlled by man-made borders. “There is a reason for these animals' existence; they just need to be managed properly at national level by government,” he says.

The aim of his study was to contribute to and combine any findings on the predation problem, and to put these findings on a macroeconomic platform to inform government of the extent of this problem in order for them to develop strategies, policies, and mitigation methods to reduce predation and lessen the impact thereof.

Thus far, excerpts from his thesis have also been published as two articles in peer-reviewed scientific journals – a peer-reviewed journal of the National Museum, Indago, as well as the journal, Frontiers in Sustainable Supply Chain Management.

With predation being a constant point of discussion at agricultural associations’ monthly meetings, he believes that the research topic he has selected for his PhD is relevant and that the outcomes of his study will be able to make a difference in the agriculture sector. His work is more than just theory. He identified a problem – the damage that predation does to the red meat industry – and found a practical solution to it.  

Students staying relevant in a fast-changing environment 

Besides the possible impact he will have on the red meat industry, the PhD was also a means to an end – to develop himself as an agricultural economist in order to become an industry expert in his field.

He also takes his role as lecturer very seriously. It is important to him that his students, once they have completed their studies, must have an actual understanding of the field and that they must be able to stay relevant in a fast-changing environment by practically applying what they have learnt. 

In his free time, Dr Van Niekerk enjoys applying his knowledge. Besides his consultancy work with farmers, he also serves on Free State Agriculture’s Young Farmer Committee, and he is a technical adviser to the National Lucerne Trust (NLT), assisting them with their grading processes to ensure that their quality system is free of any irregularities, and that they stay relevant in the industry. 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept